$DYAX Recent News Friday’s biggest gaining and

New Post Public Reply Private Reply Replies (0) Message Board

Jan 18, 2015 at 11:31 AM

$DYAX Recent News

Friday’s biggest gaining and declining stocks 1:33 p.m. June 15, 2012 - MarketWatch
Dyax shares fall 13% in preopen trade 8:07 a.m. June 15, 2012 - Greg Morcroft
Wednesday's biggest gaining and declining stocks 5:03 p.m. Dec. 2, 2009 - MarketWatch
Dyax, Santarus, CytRx soar; Hemispherx craters 11:38 a.m. Dec. 2, 2009 - Val Brickates Kennedy
Dyax leads drug stocks north 9:46 a.m. Dec. 2, 2009 - Val Brickates Kennedy
Drug stocks slide; Lundbeck slides on drug woes 2:35 p.m. June 8, 2009 - Val Brickates Kennedy
Accenture shares drop following forecast cut; Dyax falls 4:31 p.m. March 26, 2009 - Carla Mozee
Monday's biggest gaining and declining stocks 3:49 p.m. Aug. 18, 2008 - MarketWatch
Drug stocks slip, as Amylin falls on drug warning 12:45 p.m. Aug. 18, 2008 - Val Brickates Kennedy
Dyax to apply for FDA approval of DX-88 in fourth quarter 8:13 a.m. Aug. 18, 2008 - Val Brickates Kennedy
Dyax slides as potential rival files for FDA approval 4:04 p.m. March 6, 2008 - Val Brickates Kennedy
Shares in Europe rally on Buffett bond proposal 2:12 p.m. Feb. 12, 2008 - Sarah Turner
Drug stocks edge higher; Schering-Plough gains 10:40 a.m. Feb. 12, 2008 - Val Brickates Kennedy
Friday's biggest stock gainers and decliners 3:35 p.m. July 13, 2007 - Gabriel Madway
Dyax prices public offering of 10.5M shares at $3.67 a share 6:06 a.m. July 13, 2007 - Aude Lagorce
Dyax prices public offering at $3.67 a share 6:02 a.m. July 13, 2007 - Aude Lagorce
Monday's biggest stock gainers and decliners 4:06 p.m. July 9, 2007 - Gabriel Madway
Dyan files to sell 9.5 million shares 5:27 a.m. July 9, 2007 - Steve Goldstein
Dyax files to sell 9.5 million shares 5:26 a.m. July 9, 2007 - Steve Goldstein
More biotech partnerships expected 2:40 p.m. June 25, 2007 - Carolyn Pritchard

Commit To Purchase Dyax Corp At $12.50, Earn 24.9% Annualized Using Options 12:08 p.m. Dec. 24, 2014 - TheStreet.com
Can The Uptrend Continue for Dyax (DYAX)? - Tale of the Tape 8:22 a.m. Dec. 23, 2014 - Zacks.com
How Dyax Corp. (DYAX) Stock Stands Out in a Strong Industry - Tale of the Tape 8:54 a.m. Dec. 18, 2014 - Zacks.com
Can Dyax (DYAX) Keep the Earnings Streak Alive This Quarter? - Tale of the Tape 9:04 a.m. Dec. 10, 2014 - Zacks.com
Why Dyax (DYAX) Could Be an Impressive Growth Stock - Tale of the Tape 8:47 a.m. Dec. 5, 2014 - Zacks.com
Today's Weak On High Volume Stock: Dyax (DYAX) 10:00 a.m. Dec. 1, 2014 - TheStreet.com
Amgen Ends Gastric Cancer Drug Studies on Safety Review - Analyst Blog 1:20 p.m. Nov. 25, 2014 - Zacks.com
Why Intercept Pharmaceuticals (ICPT) Could Be Positioned for a Slump - Tale of the Tape 8:40 a.m. Nov. 25, 2014 - Zacks.com
Strong On High Relative Volume: Dyax (DYAX) 10:00 a.m. Nov. 24, 2014 - TheStreet.com
Why Dyax (DYAX) Could Be Positioned for a Surge? - Tale of the Tape 8:42 a.m. Nov. 7, 2014 - Zacks.com
Can Dyax (DYAX) Stock Continue to Grow Earnings? - Tale of the Tape 8:49 a.m. Nov. 4, 2014 - Zacks.com
10-Q: DYAX CORP 4:32 p.m. Nov. 3, 2014 - Edgar Online - (EDG = 10Q, 10K)
BIND Therapeutics, Inc. (BIND) Surges: Stock Rises 14.2% Higher - Tale of the Tape 8:11 a.m. Oct. 31, 2014 - Zacks.com
Update: Biotech Dyax Exceeds Q3 Estimates With The Future Looking Bright 11:15 a.m. Oct. 30, 2014 - Seeking Alpha
Will Dyax (DYAX) Continue to Surge Higher? - Tale of the Tape 8:04 a.m. Oct. 30, 2014 - Zacks.com
Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings 7:22 a.m. Oct. 30, 2014 - 247WallSt.com
Dyax's (DYAX) CEO Gustav Christiansen on Q3 2014 Results - Earnings Call Transcript 7:54 p.m. Oct. 28, 2014 - Seeking Alpha
Dyax (DYAX) Q3 2014 Results - Earnings Call Webcast 3:55 p.m. Oct. 28, 2014 - Seeking Alpha
Notable earnings after Tuesday's close 4:35 p.m. Oct. 27, 2014 - Seeking Alpha
10-Q: DYAX CORP 4:29 p.m. Aug. 1, 2014 - Edgar Online - (EDG = 10Q, 10K)

LeeAnn Ali Joins BioBridges as Executive Director, Clinical Operations 8:04 a.m. Jan. 13, 2015 - Marketwired
Technical Coverage on Biotech Stocks - Arena Pharma, XOMA, Dyax, Mast Therapeutics, and Tekmira Pharma 8:50 a.m. Jan. 2, 2015 - PR Newswire - PRF
Dyax Corp.’s First-in-Human Trial for DX-2930 Conducted by Vince and Associates Clinical Research Featured in the Annals of Allergy, Asthma & Immunology 8:01 a.m. Dec. 18, 2014 - BusinessWire - BZX
Dyax Corp. to Participate in the 25th Annual Oppenheimer Healthcare Conference 7:01 a.m. Dec. 3, 2014 - BusinessWire - BZX
Technical Snapshot on Biotech Stocks - Keryx Biopharma, Dyax, Mast Therapeutics, Cubist Pharma, and Intrexon 8:30 a.m. Dec. 1, 2014 - PR Newswire - PRF
Dyax Corp. Recognized as a “Top Place to Work” by The Boston Globe 7:30 a.m. Nov. 18, 2014 - BusinessWire - BZX
Dyax Corp. Announces Expansion of Phase 1b Clinical Trial for DX-2930 7:31 a.m. Nov. 3, 2014 - BusinessWire - BZX
Dyax Corp. Announces Third Quarter 2014 Financial Results 3:03 p.m. Oct. 28, 2014 - BusinessWire - BZX
Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 7:35 a.m. Oct. 27, 2014 - PR Newswire - PRF
Dyax Corp. to Host Third Quarter 2014 Earnings Call and Webcast 7:01 a.m. Oct. 14, 2014 - BusinessWire - BZX
Dyax Corp. to Participate in the Leerink Partners Rare Disease Roundtable 6:00 a.m. Sept. 25, 2014 - BusinessWire - BZX
Dyax Corp. Highlights Recent Progress in Licensing and Funded Research Portfolio 6:12 a.m. Sept. 22, 2014 - BusinessWire - BZX
Dyax Corp. Announces Issuance of Two Key U.S. Patents for DX-2930 6:01 a.m. Sept. 15, 2014 - BusinessWire - BZX
Biotech Equities Technical Analysis -- BioMarin Pharma, Merrimack Pharma, Sangamo BioSciences, ZIOPHARM Oncology, and Dyax 7:50 a.m. Aug. 7, 2014 - PR Newswire - PRF
Scheduled Conference Calls and Product Launches - Research Reports on Anika Therapeutics, NeoGenomics, HeartWare, Sangamo and Dyax 7:40 a.m. July 23, 2014 - PR Newswire - PRF
Dyax Corp. Announces Publication of Scientific Data for DX-2930 in Peer-Reviewed Journals 7:01 a.m. July 23, 2014 - BusinessWire - BZX
Financial Guidance, Appointments, Board Elections, and Technical Updates - Analyst Notes on Amedisys, Dyax, TearLab, Celladon and Alphatec 5:00 a.m. July 2, 2014 - PR Newswire - PRF
Pre-Market Review on Health Care Sector Equities -- Research on Dyax, Repligen, Vanda Pharma, and Ironwood Pharma 6:50 a.m. July 1, 2014 - PR Newswire - PRF
Dyax Corp. to Participate in the 2014 Wells Fargo Healthcare Conference 7:01 a.m. June 10, 2014 - BusinessWire - BZX
Dyax Corp. to Participate in the Jefferies Global Healthcare Conference 7:01 a.m. May 29, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BioMarin Strikes Deal for New Fabry Disease Therapy

BioMarin's Latest Moves in Rare Disease Therapies Now here's a plot twist in the biotechnology landscape. BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) just did what they do best—snagging rights to a promising enzyme therapy aimed at turning the tide for Fabry disease. In a deal that spoke volumes about their intentions, BioMarin is forking over a cool $70 million upfront...

SCI Faces Investigation After Earnings Downgrade

SCI's Rough Ride: Investors Brace for Impact There's nothing like waking up to find the stock you were banking on took a nosedive while you were dreaming of dividends. Service Corporation International (NYSE: SCI) sure gave shareholders more of a nightmare than a dream, slashing its earnings forecast for 2026 and watching its stock crumble by about 11.6% on October 29....

Palmetto Publishing's M&A Guide Aims to Boost Home Services

Palmetto's New Release: Mergers & Acquisitions Focus Man, Palmetto Publishing just dropped a bombshell for home services aficionados with their latest M&A guide. Now, if you’re like me, swimming in stocks and always looking for that next big exit play, this one’s tailor-made for you. Mergers and acquisitions might not sound as flashy as the tech darlings or...

Why Haunted Attractions Keep Us Coming Back for Fear

Welcome to Fear Incarnated Ah, Kansas City. More than just jazz and barbeque. You’ve got these infamous haunted houses that turn every horror flick into a mere Saturday morning cartoon. Enter Edge of Hell and Beast Haunted Attraction. Two horrifying museums of fear that somehow lure us like flies to sugar from miles away. What's the secret sauce? Well, that’s half the...

David Cornue Brings Story Insights to SXSW 2027

Crafting Stories with Precision: Cornue's Return In the world where Austin becomes a melting pot of ideas every spring, the return of David Cornue to SXSW casts a familiar, yet electrifying spark. This best-selling author and television whiz is slated to share his story magic at two workshops: one in the Lifestyle track and the other in the Film & TV track. Folks on-site...

Solink Secures $100M: NYSE Sees Tech and Sports Moves

Folks, it’s a busy day on Wall Street, with Solink leading the charge by landing over a cool $100 million in fresh funding. Let's break this down because when startups pocket nine-digit figures, it's time to pay attention. Solink's Leap Forward Now, what’s Solink doing with all that cash? They're not scrambling for coffee money, that's for sure. Instead, this funding...

Hanwha's Big Bet: Tokenizing Real-World Assets with Chainlink

Hanwha and Chainlink: A Game Changer in Tokenization What do Hanwha Investment & Securities, a heavyweight in Korea's finance scene, and Chainlink, the wizard of onchain finance, think they're up to? They're buddies now, locked and loaded, to tokenize real-world assets (RWAs). They're not just shaking hands; they're aiming to jiggle the global finance bedrock....

Skechers Faces Shareholder Lawsuit: Must Act by Dec 21

Skechers Shareholders Stirring Over Lawsuit A fresh wave of legal antics is crashing at the shores of Skechers U.S.A., Inc. (NYSE: SKX) as frustrated shareholders mobilize against the footwear juggernaut. We're talking about a class action lawsuit here, folks, aimed at shaking down some clarity—or maybe just some cold, hard cash—from this bruiser over some sketchy...

OPC Energy Refinances $825M for U.S. Power Plants

Strategic Financial Move for OPC Energy Here's the scoop from the powerhouse behind some major U.S. electricity moves: OPC Energy and its subsidiary CPV nailed down a hefty $825 million financing package for the Shore and Maryland power plants. This isn’t just any old financial shuffle. Nope, they've hammered out an all-in-one refinancing deal that's setting the stage...

wagamama Spruces Up U.S. Market with mamago Launch

What's Cooking at wagamama with mamago? Here comes wagamama, striding into the American dining scene with that familiar bold Pan-Asian flair, now offering more than just a seat at their tables. The fresh move to a direct-to-door model dubbed ‘mamago’ ushers in an era where their signature dishes don't just seduce your taste buds at their restaurants. Nope, they are...